血小板TLT-1在健康供者及出血血栓风险患者中的调控研究
本研究探讨血小板α颗粒蛋白TLT-1的分子释放机制及其作为血小板功能障碍生物标志物的价值。体外实验显示TLT-1经ADAM10/ADAM17金属蛋白酶依赖方式水解,剪切应力、GPVI配体或活化因子X可触发其释放。创伤患者血浆sTLT-1升高,与创伤诱导性凝血病(TIC)及损伤严重度相关,对TIC具有判别效能(AUC 0.78)。
要点
- TLT-1经ADAM10/ADAM17金属蛋白酶依赖水解,释放10–17 kDa片段。
- 与GPVI不同,PAR-1活化后血小板TLT-1暴露增加。
- 创伤患者sTLT-1与TIC及损伤严重度相关,AUC 0.78。
核心结论
- TLT-1在活化血小板上增加,受ADAM10和ADAM17调控。
- TLT-1释放由剪切应力、GPVI配体或活化因子X触发。
- 血浆sTLT-1与创伤严重度和TIC相关。
研究设计与样本
- 体外评估GPVI配体、凝血或剪切应力暴露后血小板TLT-1动态,采用ELISA和免疫印迹。
- 检测创伤或接受MCS治疗患者及健康供者血浆sTLT-1。
- 评估sTLT-1与TIC、损伤严重度和死亡率的关联。
主要发现
- TLT-1水解为10–17 kDa片段,为金属蛋白酶依赖,可被ADAM10和ADAM17抑制阻断。
- 与GPVI不同,PAR-1活化后血小板TLT-1暴露增加。
- 创伤患者sTLT-1较对照升高,与TIC相关(P < .05),与损伤严重度相关(P < .01)。
- ROC分析显示sTLT-1对TIC具判别效能(AUC 0.78;P = .011),Youden截断值1.180 ng/mL,灵敏度89%,特异度73%。
- 血小板TLT-1基础表达,活化后动员2.5倍,GPVI连接和血浆复钙后脱落;剪切暴露血小板及MCS患者血浆sTLT-1升高。
关键数值与推荐
- sTLT-1判别TIC的AUC为0.78(P = .011),Youden截断值1.180 ng/mL,灵敏度89%,特异度73%。
- 血小板TLT-1活化后动员2.5倍。
临床怎么用
- 血浆sTLT-1或可作为创伤患者TIC和损伤严重度的生物标志物。
- TLT-1释放机制涉及ADAM10/ADAM17,或为血小板功能障碍干预提供靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Triggering receptor expressed on myeloid cells-like transcript 1 (TLT-1), a platelet-specific α-granule protein, is implicated in hemostasis, but its regulation remains unclear. Platelet dysfunction contributes to trauma-induced coagulopathy (TIC) and thrombotic complications in trauma or mechanical circulatory support (MCS); however, underlying mechanisms remain poorly understood. OBJECTIVES: This study investigated the molecular mechanisms underlying soluble TLT (sTLT)-1 release and its role as a biomarker of platelet dysfunction in patients with severe trauma or receiving MCS. METHODS: TLT-1 dynamics on platelets exposed to glycoprotein (GP)VI ligand, coagulation, or shear stress in vitro were evaluated by ELISA and immunoblotting. sTLT-1 was measured in plasma from trauma or MCS-treated patients and healthy donors. Associations with TIC, injury severity, and mortality were assessed. RESULTS: Proteolysis of TLT-1 to release a 10- to 17-kDa fragment was metalloproteinase dependent and blocked by ADAM10 and ADAM17 inhibition. Unlike GPVI, platelet TLT-1 exposure increased following PAR-1 activation. sTLT-1 was elevated in trauma patients compared with controls and correlated with TIC (P < .05) and injury severity (P < .01). Receiver-operating characteristic analysis demonstrated discriminatory performance for TIC (area under the curve, 0.78; P = .011), with a Youden cutoff of 1.180 ng/mL yielding 89% sensitivity and 73% specificity. Platelet TLT-1 was basally expressed, mobilized 2.5-fold with activation, and shed in response to GPVI ligation and plasma recalcification. Shear-exposed platelets and plasma from MCS-treated patients exhibited elevated sTLT-1 levels. CONCLUSION: Unlike GPVI, TLT-1 increased on activated platelets and was regulated by ADAM10 and ADAM17. TLT-1 release is triggered by shear stress, GPVI ligands or activated factor X. Plasma sTLT-1 was associated with trauma severity and TIC.
引用
- Kaur A, Ali SA, Alim M, et al. Platelet triggering receptor expressed on myeloid cells-like transcript 1 regulation in healthy donors and patients at risk of bleeding and thrombosis. J Thromb Haemost. 2026. PMID: 42297145. doi:10.1016/j.jtha.2026.06.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。